Successful treatment with sorafenib in patients with advanced hepatocellular carcinoma: clinical case

Multi-kinase inhibitor sorafenib is the only one drug which increases life time in patients with advanced hepatocellular carcinoma (HCC). Results from the SHARP trial showed that median progression-free survival was less than 5 months. However, it is possible to achieve strong treatment effect for s...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Yu V Bisovskaya, V V Breder, B M Medvedeva, V A Gorbunova
Aineistotyyppi: Artigo
Kieli:Russo
Julkaistu: IP Habib O.N. 2014-06-01
Sarja:Современная онкология
Aiheet:
hepatocellular carcinoma
sorafenib
chronic hepatitis b
lamivudine
Linkit:https://modernonco.orscience.ru/1815-1434/article/view/26969
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia